LYPD1 (LY6/PLAUR domain containing 1) is a secreted protein that functions primarily as an anti-angiogenic factor and modulator of cellular processes. The protein demonstrates potent anti-angiogenic properties, with cardiac fibroblasts using LYPD1 to inhibit vascular endothelial cell sprouting and network formation 1. This anti-angiogenic activity is regulated by the transcription factor GATA6, which controls LYPD1 expression in cardiac fibroblasts 2. LYPD1 is expressed throughout the central nervous system 3 and appears in various pathological contexts. In systemic sclerosis, serum LYPD1 levels correlate with skin thickness scores and IL-6 levels, suggesting its potential as a biomarker for monitoring skin fibrosis 4. The protein has emerged as a therapeutic target in cancer treatment, being broadly expressed in ovarian cancer (~70% prevalence in serous subtype) where bispecific antibodies targeting LYPD1 and CD3 demonstrate significant anti-tumor activity 56. Additionally, LYPD1 shows prognostic value in bladder cancer, where its overexpression inhibits cell proliferation, migration, and invasion 7. The protein is also included in prognostic models for lung adenocarcinoma based on exosome-derived genes 8.